NY A00960

Requires insurance policies providing hospital, major medical, or comprehensive coverage to include FDA-approved medications, medical devices, and products for treating withdrawal symptoms as part of substance use disorder treatment coverage.

Mandates immediate coverage without prior authorization for buprenorphine, methadone, long-acting injectable naltrexone, and FDA-approved medical devices or products for withdrawal symptom treatment in large group plans.

Applies the same financial requirements and treatment limitations to substance use disorder benefits as those applied to other medical and surgical benefits covered by insurance policies.

Takes effect immediately and applies to all insurance policies and contracts issued, renewed, modified, altered, or amended on or after the effective date.